Cabergoline use and risk of fibrosis and insufficiency of cardiac valves: Meta-analysis of observational studies

Herz

Volumn 38, Issue 8, 2013, Pages 868-880

  De Vecchis, R ^a   Esposito, C ^b   Ariano, C ^a  

^a Cardiology Unit   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cabergoline; Fibrosis; Meta analysis; Parkinson's disease; Valvular regurgitation

Indexed keywords

CABERGOLINE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

AORTA VALVE REGURGITATION; ARTICLE; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR PARAMETERS; DISEASE SEVERITY; HEART MUSCLE FIBROSIS; HEART VALVE CALCIFICATION; HEART VALVE FIBROSIS; HEART VALVE REGURGITATION; HUMAN; HYPERPROLACTINEMIA; MITRAL VALVE REGURGITATION; MITRAL VALVE TENTING AREA; OBSERVATIONAL STUDY; PARKINSON DISEASE; SYSTEMATIC REVIEW; TRICUSPID VALVE REGURGITATION;

DOPAMINE AGONISTS; ERGOLINES; FEMALE; FIBROSIS; HEART VALVE DISEASES; HUMANS; MALE; MYOCARDIUM; OBSERVATIONAL STUDY AS TOPIC; PREVALENCE; RISK FACTORS;

EID: 84891273904     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-013-3816-0     Document Type: Article

References (46)

1. Zanettini R, Antonini A, Gatto G et al (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39-46
2. Schade R, Andersohn F, Suissa S et al (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29-38
3. Roth BL (2007) Drugs and valvular heart disease. N Engl J Med 356:6-9
4. Valassi E, Klibanski A, Biller BM (2010) Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 95(3):1025-1033
5. Moller JE, Connolly HM, Rubin J et al (2003) Factors associated with progression of carcinoid heart disease. N Engl J Med 348:1005-1015
6. Fox DJ, Khattar RS (2004) Carcinoid heart disease: presentation, diagnosis, and management. Heart 90:1224-1228
7. Kars M, Pereira AM, Bax JJ, Romijn JA (2008) Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 159(4):363-367 (Epub 14 Aug 2008)
8. Boguszewski CL, Santos CM dos, Sakamoto KS et al (2012) A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary 15(1):44-49
9. Corvol JC, Anzouan-Kacou JB, Fauveau E et al (2007) Heart valve regurgitation, pergolide use, and Parkinson disease: an observational study and meta-analysis. Arch Neurol 64:1721-1726
10. Simonis G, Fuhrmann JT, Strasser RH (2007) Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists. Mov Disord 22(13):1936-1942
11. Rasmussen VG, Østergaard K, Dupont E, Poulsen SH (2011) The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists. Mov Disord 26(5):801-806
12. Bogazzi F, Manetti L, Raffaelli V et al (2008) Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest 31(12):1119-1123
13. Inzelberg R, Schechtman E, Nisipeanu P (2003) Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs Aging 20(11):847-855
14. D'Avella R, Comanducci T, Roghi A et al (2011) Morbo di Parkinson: dall'analisi farmaco-epidemiologica alla definizione di un percorso per la gestione del paziente cronico (abstract; italian) in: ISTISAN: XX Seminario nazionale su-La valutazione dell'uso e della sicurezza dei farmaci: esperienze in Italiaâ€-, Italian National Health Institute, Rome
15. Dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR (2011) Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary 14:259-265
16. Pinzone JJ, Katznelson L, Danila DC et al (2000) Primary medical therapy of micro-and macroprolactinomas in men. J Clin Endocrinol Metab 85(9):3053-3057
17. Food and Drug Administration (2007) Withdrawal of Parkinson's treatment: pergolide. http://www.fda.gov/ForConsumers/Consumer Updates/ucm048819.htm. Accessed 15 Feb 2011
18. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700
19. Kenangil G, Ozekmekci S, Koldas L et al (2007) Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline. Clin Neurol Neurosurg 109:350-353
20. Rasmussen VG, Poulsen SH, Dupont E et al (2008) Heart valve desease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease. J Intern Med 263:90-98
21. Yamashiro K, Komine-Kobayashi M, Hatano T et al (2008) The frequency of cardiac valvular regurgitation in Parkinson's disease. Mov Disord 23(7):935-941
22. Vallette S, Serri K, Rivera J et al (2009) Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 12(3):153-157
23. Peralta C, Wolf E, Alber H et al (2006) Valvular heart disease in Parkinson's disease vs. controls: an echocardiographic study. Mov Disord 21(8):1109-1113
24. Yamamoto M, Uesugi T, Nakayama T (2006) Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 67(7):1225-1229
25. Junghanns S, Fuhrmann JT, Simonis G et al (2007) Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord 22:234-238
26. Trifirò G, Mokhles MM, Dieleman JP et al (2012) Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control Study. Drug Saf 35(2):159-171
27. Lancellotti P, Livadariu E, Markov M et al (2008) Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 159:1-5
28. Bogazzi F, Buralli S, Manetti L et al (2008) Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract 62(12):1864-1869
29. Kars M, Delgado V, Holman ER et al (2008) Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 93(9):3348-3356
30. Wakil A, Rigby AS, Clark AL et al (2008) Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 159(4):R11-R14
31. Colao A, Galderisi M, Di Sarno A et al (2008) Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 93(10):3777-3784
32. Herring N, Szmigielski C, Becher H et al (2009) Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 70(1):104-108
33. Arranz MJ, Leon J de (2007) Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 12:707-747
34. Malhotra AK, Lencz T, Correll CU, Kane JM (2007) Genomics and the future of pharmacotherapy in psychiatry. Int Rev Psychiatry 19:523-530
35. Izgi C, Feray H, Cevik C et al (2010) Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly. J Heart Valve Dis 19(6):797-800
36. Bhat MH, Mushtaq S, Saba S et al (2011) Cabergoline-induced tricuspid regurgitation: case report and review of literature. Indian J Endocrinol Metab 15(2):137-139
37. Irwin RB, Luckie M, Khattar RS (2010) Tricuspid regurgitation: contemporary management of a neglected valvular lesion. Postgrad Med J 86(1021):648-655
38. Moerman VM, Dewilde D, Hermans K (2012) Carcinoid heart disease: typical findings on echocardiography and cardiac magnetic resonance. Acta Cardiol 67(2):245-248
39. Maisch B, Christ M (2004) Extracardiac causes of right ventricular insufficiency. Internist (Berl) 45(10):1136-1146 (Article in German)
40. Simula DV, Edwards WD, Tazelaar HD et al (2002) Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc 77(2):139-147
41. Thapa R, Dawn B, Nath J (2012) Tricuspid regurgitation: pathophysiology and management. Curr Cardiol Rep 14(2):190-199
42. Zoghbi WA, Enriquez-Sarano M, Foster E et al (2003) American society of echocardiography. recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16(7):777-802
43. Van Camp G, Flamez A, Cosyns B et al (2004) Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179-1183
44. Kim JY, Chung EJ, Park SW, Lee WY (2006) Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists. Mov Disord 21:1261-1264
45. Kvernmo T, Hartter S, Burger E (2006) A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 28:1065-1078
46. Jahnichen S, Horowski R, Pertz HH (2005) Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 513:225-228